The Korean Journal of Physiology and Pharmacology

The Korean Society of Pharmacology (대한약리학회)
권호 표지
DOI QR코드

DOI QR Code

Insulin Like Growth Factor Binding Protein-5 Regulates Excessive Vascular Smooth Muscle Cell Proliferation in Spontaneously Hypertensive Rats via ERK 1/2 Phosphorylation

  • Lee, Dong Hyup (Department of Thoracic and Cardiovascular Surgery, College of Medicine, Yeungnam University) ;
  • Kim, Jung Eun (Department of Pharmacology, College of Medicine, Yeungnam University) ;
  • Kang, Young Jin (Department of Pharmacology, College of Medicine, Yeungnam University)
  • Received : 2012.11.16
  • Accepted : 2013.02.04
  • Published : 2013.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

Insulin-like growth factor binding proteins (IGFBPs) are important components of insulin growth factor (IGF) signaling pathways. One of the binding proteins, IGFBP-5, enhances the actions of IGF-1, which include the enhanced proliferation of smooth muscle cells. In the present study, we examined the expression and the biological effects of IGFBP-5 in vascular smooth muscle cells (VSMCs) from spontaneously hypertensive rats (SHR) and Wistar Kyoto rats (WKY). The levels of IGFBP-5 mRNA and protein were found to be higher in the VSMC from SHR than in those from WKY. Treatment with recombinant IGFBP-5-stimulated VSMC proliferation in WKY to the levels observed in SHR. In the VSMCs of WKY, incubation with angiotensin (Ang) II or IGF-1 dose dependently increased IGFBP-5 protein levels. Transfection with IGFBP-5 siRNA reduced VSMC proliferation in SHR to the levels exhibited in WKY. In addition, recombinant IGFBP-5 significantly up-regulated ERK1/2 phosphorylation in the VSMCs of WKY as much as those of SHR. Concurrent treatment with the MEK1/2 inhibitors, PD98059 or U0126 completely inhibited recombinant IGFBP-5-induced VSMC proliferation in WKY, while concurrent treatment with the phosphatidylinositol-3 kinase inhibitor, LY294002, had no effect. Furthermore, knockdown with IGFBP-5 siRNA inhibited ERK1/2 phosphorylation in VSMC of SHR. These results suggest that IGFBP-5 plays a role in the regulation of VSMC proliferation via ERK1/2 MAPK signaling in hypertensive rats.

Keywords

References

  1. Delafontaine P, Song YH, Li Y. Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels. Arterioscler Thromb Vasc Biol. 2004;24:435-444. https://doi.org/10.1161/01.ATV.0000105902.89459.09
  2. Clemmons DR. Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer. Nat Rev Drug Discov. 2007;6:821-833. https://doi.org/10.1038/nrd2359
  3. Duan C. Specifying the cellular responses to IGF signals: roles of IGF-binding proteins. J Endocrinol. 2002;175:41-54. https://doi.org/10.1677/joe.0.1750041
  4. Hsieh T, Gordon RE, Clemmons DR, Busby WH Jr, Duan C. Regulation of vascular smooth muscle cell responses to insulinlike growth factor (IGF)-I by local IGF-binding proteins. J Biol Chem. 2003;278:42886-42892. https://doi.org/10.1074/jbc.M303835200
  5. Zheng B, Clarke JB, Busby WH, Duan C, Clemmons DR. Insulin-like growth factor-binding protein-5 is cleaved by physiological concentrations of thrombin. Endocrinology. 1998; 139:1708-1714. https://doi.org/10.1210/endo.139.4.5945
  6. Duan C, Hawes SB, Prevette T, Clemmons DR. Insulin-like growth factor-I (IGF-I) regulates IGF-binding protein-5 synthesis through transcriptional activation of the gene in aortic smooth muscle cells. J Biol Chem. 1996;271:4280-4288. https://doi.org/10.1074/jbc.271.8.4280
  7. Kuemmerle JF, Zhou H. Insulin-like growth factor-binding protein-5 (IGFBP-5) stimulates growth and IGF-I secretion in human intestinal smooth muscle by Ras-dependent activation of p38 MAP kinase and Erk1/2 pathways. J Biol Chem. 2002; 277:20563-20571. https://doi.org/10.1074/jbc.M200885200
  8. Intengan HD, Schiffrin EL. Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis. Hypertension. 2001;38:581-587. https://doi.org/10.1161/hy09t1.096249
  9. Resink TJ, Scott-Burden T, Baur U, Bühler FR. Increased proliferation fate and phosphoinositide turnover in cultured smooth muscle cells from spontaneously hypertensive rats. J Hypertens Suppl. 1987;5:S145-S148. https://doi.org/10.1097/00004872-198712004-00025
  10. Choi HC, Lee KY, Lee DH, Kang YJ. Heme oxygenase-1 induced by aprotinin inhibits vascular smooth muscle cell proliferation through cell cycle arrest in hypertensive rats. Korean J Physiol Pharmacol. 2009;13:309-313. https://doi.org/10.4196/kjpp.2009.13.4.309
  11. Vecchione C, Colella S, Fratta L, Gentile MT, Selvetella G, Frati G, Trimarco B, Lembo G. Impaired insulin-like growth factor I vasorelaxant effects in hypertension. Hypertension. 2001;37:1480-1485. https://doi.org/10.1161/01.HYP.37.6.1480
  12. Grant MB, Wargovich TJ, Ellis EA, Tarnuzzer R, Caballero S, Estes K, Rossing M, Spoerri PE, Pepine C. Expression of IGF-I, IGF-I receptor and IGF binding proteins-1, -2, -3, -4 and -5 in human atherectomy specimens. Regul Pept. 1996;67:137-144. https://doi.org/10.1016/S0167-0115(96)00124-3
  13. Colao A, Spiezia S, Di Somma C, Pivonello R, Marzullo P, Rota F, Musella T, Auriemma RS, De Martino MC, Lombardi G. Circulating insulin-like growth factor-I levels are correlated with the atherosclerotic profile in healthy subjects independently of age. J Endocrinol Invest. 2005;28:440-448. https://doi.org/10.1007/BF03347225
  14. Kawachi S, Takeda N, Sasaki A, Kokubo Y, Takami K, Sarui H, Hayashi M, Yamakita N, Yasuda K. Circulating insulin-like growth factor-1 and insulin-like growth factor binding protein-3 are associated with early carotid atherosclerosis. Arterioscler Thromb Vasc Biol. 2005;25:617-621. https://doi.org/10.1161/01.ATV.0000154486.03017.35
  15. Schuler-Luttmann S, Monnig G, Enbergs A, Schulte H, Breithardt G, Assmann G, Kerber S, von Eckardstein A. Insulin-like growth factor-binding protein-3 is associated with the presence and extent of coronary arteriosclerosis. Arterioscler Thromb Vasc Biol. 2000;20:E10-E15. https://doi.org/10.1161/01.ATV.20.4.e10
  16. Watanabe T, Itokawa M, Nakagawa Y, Iguchi T, Katagiri T. Increased levels of insulin-like growth factor binding protein-3 in hypertensive patients with carotid atherosclerosis. Am J Hypertens. 2003;16:754-760. https://doi.org/10.1016/S0895-7061(03)00985-3
  17. Kim KS, Seu YB, Baek SH, Kim MJ, Kim KJ, Kim JH, Kim JR. Induction of cellular senescence by insulin-like growth factor binding protein-5 through a p53-dependent mechanism. Mol Biol Cell. 2007;18:4543-4552. https://doi.org/10.1091/mbc.E07-03-0280
  18. Bach LA. The insulin-like growth factor system in kidney disease and hypertension. Curr Opin Nephrol Hypertens. 2012;21:86-91. https://doi.org/10.1097/MNH.0b013e32834dc1a2
  19. Schneider MR, Wolf E, Hoeflich A, Lahm H. IGF-binding protein-5: flexible player in the IGF system and effector on its own. J Endocrinol. 2002;172:423-440. https://doi.org/10.1677/joe.0.1720423
  20. Duan C, Liimatta MB, Bottum OL. Insulin-like growth factor (IGF)-I regulates IGF-binding protein-5 gene expression through the phosphatidylinositol 3-kinase, protein kinase B/Akt, and p70 S6 kinase signaling pathway. J Biol Chem. 1999;274:37147-37153. https://doi.org/10.1074/jbc.274.52.37147
  21. Cobb LJ, Salih DA, Gonzalez I, Tripathi G, Carter EJ, Lovett F, Holding C, Pell JM. Partitioning of IGFBP-5 actions in myogenesis: IGF-independent anti-apoptotic function. J Cell Sci. 2004;117:1737-1746. https://doi.org/10.1242/jcs.01028
  22. Butt AJ, Dickson KA, McDougall F, Baxter RC. Insulin-like growth factor-binding protein-5 inhibits the growth of human breast cancer cells in vitro and in vivo. J Biol Chem. 2003; 278:29676-29685. https://doi.org/10.1074/jbc.M301965200
  23. Salih DA, Tripathi G, Holding C, Szestak TA, Gonzalez MI, Carter EJ, Cobb LJ, Eisemann JE, Pell JM. Insulin-like growth factor-binding protein 5 (Igfbp5) compromises survival, growth, muscle development, and fertility in mice. Proc Natl Acad Sci USA. 2004;101:4314-4319. https://doi.org/10.1073/pnas.0400230101
  24. Hampel B, Fortschegger K, Ressler S, Chang MW, Unterluggauer H, Breitwieser A, Sommergruber W, Fitzky B, Lepperdinger G, Jansen-Dürr P, Voglauer R, Grillari J. Increased expression of extracellular proteins as a hallmark of human endothelial cell in vitro senescence. Exp Gerontol. 2006;41:474-481. https://doi.org/10.1016/j.exger.2006.03.001
  25. Lau KH, Baylink DJ. Molecular mechanism of action of fluoride on bone cells. J Bone Miner Res. 1998;13:1660-1667. https://doi.org/10.1359/jbmr.1998.13.11.1660
  26. Wang J, Razuvaev A, Folkersen L, Hedin E, Roy J, Brismar K, Hedin U. The expression of IGFs and IGF binding proteins in human carotid atherosclerosis, and the possible role of IGF binding protein-1 in the regulation of smooth muscle cell proliferation. Atherosclerosis. 2012;220:102-109. https://doi.org/10.1016/j.atherosclerosis.2011.10.032

Cited by

  1. Upregulation of miR-197 inhibits cell proliferation by directly targeting IGFBP5 in human uterine leiomyoma cells vol.51, pp.8, 2015, https://doi.org/10.1007/s11626-015-9887-x
  2. miR-143 regulates proliferation and differentiation of bovine skeletal muscle satellite cells by targeting IGFBP5 vol.53, pp.3, 2013, https://doi.org/10.1007/s11626-016-0109-y
  3. 40 YEARS OF IGF1: Role of IGF-binding proteins in regulating IGF responses to changes in metabolism vol.61, pp.1, 2013, https://doi.org/10.1530/jme-18-0016
  4. Homocysteine downregulates cardiac homeobox transcription factor NKX2.5 via IGFBP5 vol.319, pp.6, 2013, https://doi.org/10.1152/ajpheart.00347.2020
  5. Silence of Insulin-Like Growth Factor 2 mRNA-Binding Protein 1 Prevents Vascular Smooth Muscle Cells Proliferation via Nuclear Factor of Activated T Cells Isoform-3/Ca2+/Calmodulin Pathway vol.11, pp.4, 2013, https://doi.org/10.1166/jbt.2021.2747